Brief: Alpine Immune Sciences Reports FDA Partial Clinical Hold On Neon-2 Trial Of Davoceticept

Alpine Immune Sciences

07/03/2022 13:14

March 7 (Reuters) - Alpine Immune Sciences Inc  ALPN.O :
    * ALPINE IMMUNE SCIENCES REPORTS FDA PARTIAL CLINICAL HOLD ON NEON-2 TRIAL
OF
DAVOCETICEPT (ALPN-202) IN COMBINATION WITH PEMBROLIZUMAB
    * ALPINE IMMUNE SCIENCES INC - NEON-1 STUDY OF ALPN-202 AS A MONOTHERAPY IS
UNAFFECTED
    * ALPINE IMMUNE SCIENCES INC - PARTIAL CLINICAL HOLD WAS PROMPTED BY
ALPINE'S
REPORT OF A GRADE 5 SERIOUS ADVERSE EVENT (PATIENT DEATH) IN NEON-2 TRIAL
    * ALPINE IMMUNE SCIENCES INC - PATIENTS CURRENTLY ENROLLED IN NEON-2 TRIAL
MAY
CONTINUE TO RECEIVE DAVOCETICEPT AND PEMBROLIZUMAB
    * ALPINE IMMUNE - PARTICIPANT'S DEATH WAS ATTRIBUTED TO CARDIOGENIC SHOCK,
CONSIDERED BY TREATING PHYSICIANS AS LIKELY RELATED TO IMMUNE-MEDIATED
MYOCARDITIS
    * ALPINE IMMUNE SCIENCES INC - NO ADDITIONAL PATIENTS MAY BE ENROLLED IN
NEON-2
TRIAL UNTIL PARTIAL CLINICAL HOLD IS RESOLVED

Source text for Eikon:  ID:nBwbDpv5Ga 
Further company coverage:  ALPN.O 

 ((Reuters.Briefs@thomsonreuters.com;))